Hepatitis delta virus super-infection in a co-infected patient with the human immunodeficiency virus type 1 and a surface antigen-negative hepatitis B virus variant

International Journal of STD and AIDS

Volumn 17, Issue 9, 2006, Pages 635-638

  Gordien, Emmanuel ^a   Bouhassoune, Karim ^a   Calboreanu, Alexandrina ^b   Alloui, Chakib ^a   Rico Garcia, Maité ^a   Salmon Céron, Dominique ^b   Legal, Frédéric ^a   Dény, Paul ^a   Sogni, Philippe ^b   Podevin, Philippe ^b  

^a UNIVERSITÉ PARIS 13   (France)

^b Université Paris 5 ^*  (France)

Author keywords

HDV; HIV; HNV variant

Indexed keywords

ANTIRETROVIRUS AGENT; EFAVIRENZ; LAMIVUDINE; MEMBRANE ANTIGEN; PEGINTERFERON; TENOFOVIR; ZIDOVUDINE;

ACUTE HEPATITIS; ADULT; ANAMNESIS; ARTICLE; CASE REPORT; CHRONIC HEPATITIS; DELTA AGENT HEPATITIS; DISEASE ASSOCIATION; DRUG RESISTANCE; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS DELTA VIRUS; HOMOSEXUALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LABORATORY TEST; LIVER BIOPSY; MALE; PRIORITY JOURNAL; SUPERINFECTION; VIRUS MUTANT;

ADENINE; ALANINE TRANSAMINASE; AMINO ACID SEQUENCE; ANTI-HIV AGENTS; FOLLOW-UP STUDIES; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS D; HIV INFECTIONS; HIV-1; HOMOSEXUALITY, MALE; HUMANS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; PHOSPHONIC ACIDS; RNA, VIRAL; SUPERINFECTION; TIME FACTORS; VIRAL LOAD;

EID: 33748355138     PISSN: 09564624     EISSN: 09564624     Source Type: Journal    
DOI: 10.1258/095646206778113159     Document Type: Article

References (10)

1. Benhamou Y, Bochet M, Thibault V, et al. Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients. Hepatology 1999;30:1302-6
2. Ivaniushina V, Radjef N, Alexeeva M, et al. Hepatitis delta virus genotypes I and II cocirculate in an endemic area of Yakutia, Russia. J Gen Virol 2001;82:2709-18
3. Sulkowski MS, Thomas DL, Mehta SH, Chaisson RE, Moore RD. Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. Hepatology 2002;35:182-9
4. Manegold C, Hannoun C, Wywiol A, et al. Reactivation of hepatitis B virus replication accompanied by acute hepatitis in patients receiving highly active antiretroviral therapy. Clin Infect Dis 2001;32:144-8
5. Fujii H, Moriyama K, Sakamoto N, et al. Gly145 to Arg substitution in HBs antigen of immune escape mutant of hepatitis B virus. Biochem Biophys Res Commun 1992;184:1152-1157
6. Wallace LA, Echevarria JE, Echevarria JM, Carman WF. Molecular characterization of envelope antigenic variants of hepatitis B virus from Spain. J Infect Dis 1994;170:1300-3
7. Ling R, Harrison TJ. Functional analysis of mutations conferring lamivudine resistance on hepatitis B virus. J Gen Virol 1999;80:601-6
8. Prange R, Mangold CM, Hilfrich R, Streeck RE. Mutational analysis of HBsAg assembly. Intervirology 1995;38:16-23
9. Carman WF, Korula J, Wallace L, MacPhee R, Mimms L, Decker R. Fulminant reactivation of hepatitis B due to envelope protein mutant that escaped detection by monoclonal HBsAg ELISA. Lancet 1995;345:1406-7
10. O'Malley B, Lazinski D. A hepatitis B surface antigen mutant that lacks the antigenic loop region can self-assemble and interact with the large hepatitis delta antigen. J Virol 2002;76:10060-3